Brain-penetrant class I ampakine with AMPA receptor (AMPAR; iGluR) positive allosteric modulator (PAM) activity both in vitro and in vivo.
CX614 (BDP-37) is a brain-penetrant class I ampakine (benzoxazine subgroup of benzamide-type) with AMPA receptor (AMPAR; iGluR) positive allosteric modulator (PAM) activity via targeting a binding site shared by cyclothiazide (CTZ), but distinct from that of GYKI 52466. CX614 enhances field excitatory postsynaptic potentials (amplitude & duration) in rat hippocampal slices and autaptically evoked excitatory postsynaptic currents in neuronal cultures (EC50 of 20-40 μM) by blocking desensitization and slowing deactivation of responses to glutamate. CX614 is also widely employed for studying AMPAR-mediated physiological responses in vivo (1-10 mg/kg n rats and mice via i.p.).
It was previously reported that Stargazin (STG) enhances the surface expression of AMPA receptors, controls receptor gating and slows channel desensitization as an auxiliary subunit of the receptors. Ampakines are a class of AMPA receptor positive allosteric modulators that modify
Mounting evidence suggests that trophic cell signaling can be mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation. It has been demonstrated that exogenous application of brain-derived neurotrophic factor (BDNF) is highly neuroprotective in vitro against neurotoxic insults such as standard chemotherapies.
It has been proposed that glutamatergic and dopaminergic systems are functionally opposed in their regulation of striatal output. The present study tested the effects of drugs that enhance AMPA-receptor-mediated glutamatergic transmission (ampakines) for their effects on dopamine-related alterations in cortical
The 5-year survival rate of glioblastoma (GBM) is ~10%, demonstrating that a new therapeutic modality for this cancer is desperately needed. Complicating the search for such a modality is that most large molecules cannot pass through the blood brain barrier
Among neurobiological mechanisms underlying antidepressant properties of ketamine, structural remodeling of prefrontal and hippocampal neurons has been proposed as critical. The suggested mechanism involves downstream activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which trigger mammalian target of rapamycin (mTOR)-dependent structural plasticity